Fly News Breaks for February 4, 2020
Feb 4, 2020 | 08:23 EDT
Craig-Hallum analyst Francois Brisebois initiated coverage of Galmed with a Buy rating and $18 price target. The analyst notes that the company is an original NASH contender with a "strong" safety/efficacy profile that remains under the radar during Phase 3/4 enrollment.
News For GLMD From the Last 2 Days
There are no results for your query GLMD